Exelixis
EXEL
#1329
Rank
โ‚น1.603 T
Marketcap
โ‚น6,573
Share price
0.58%
Change (1 day)
79.08%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): โ‚น23.20

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น324.99. In 2022 the company made an earnings per share (EPS) of โ‚น53.54 a decrease over its 2021 EPS that were of โ‚น69.51.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)โ‚น23.20-56.67%
2022โ‚น53.54-22.97%
2021โ‚น69.51100%
2020โ‚น34.75-65.09%
2019โ‚น99.56-53.91%
2018โ‚น216.03333.96%
2017โ‚น49.78-260.61%
2016-โ‚น31.00-58.75%
2015-โ‚น75.14-42.45%
2014-โ‚น130.565.3%
2013-โ‚น123.9843.48%
2012-โ‚น86.41-264.29%
2011โ‚น52.60-165.88%
2010-โ‚น79.84-32.54%
2009-โ‚น118.35-17.65%
2008-โ‚น143.7175.86%
2007-โ‚น81.72-25.64%
2006-โ‚น109.908.33%
2005-โ‚น101.44-42.86%
2004-โ‚น177.5230.34%
2003-โ‚น136.19-5.23%
2002-โ‚น143.71-0.65%
2001-โ‚น144.65-51.87%
2000-โ‚น300.57

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
โ‚น627.87 93.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น71.38-78.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1,524 368.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น178.74-45.00%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น93.24-71.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น424.55 30.64%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚น270.26-16.84%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-โ‚น1,336-510.98%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น78.90-124.28%๐Ÿ‡บ๐Ÿ‡ธ USA